Unapproved Drugs Identified in Androgen Receptor Modulators

Share this content:
Unapproved Drugs Identified in Androgen Receptor Modulators
Unapproved Drugs Identified in Androgen Receptor Modulators

WEDNESDAY, Nov. 29, 2017 (HealthDay News) -- Products marketed as selective androgen receptor modulators and sold via the internet frequently contain unapproved drugs and substances, and the amount of active compound often does not match that listed on the label, according to a study published in the Nov. 28 issue of the Journal of the American Medical Association.

Ryan M. Van Wagoner, Ph.D., from the Sports Medicine Research and Testing Laboratory in Salt Lake City, and colleagues analyzed the chemical identity and amounts of ingredients in dietary supplements and products that are marketed and sold via the internet as selective androgen receptor modulators.

The researchers found that 23 of the 44 products marketed and sold as selective androgen receptor modulators contained one or more selective androgen receptor modulator. Another unapproved drug was identified in an additional 17 products, including the growth hormone secretagogue ibutamoren, the peroxisome proliferator-activated receptor-δ agonist GW501516, and the Rev-ErbA agonist SR9009. Four products had no active compound, and 11 contained substances not listed on the label. The amount of active compound in the product matched that listed on the label in 18 of the products. In 26 of the products, the quantity of the compounds listed on the label differed substantially from that found by analysis.

"In this limited investigation involving chemical analyses of 44 products marketed as selective androgen receptor modulators and sold via the internet, most products contained unapproved drugs and substances," the authors write. "Only 52 percent contained selective androgen receptor modulators and many were inaccurately labeled."

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »